BMY Bristol-Myers Squibb Company Common Stock
关于 Bristol-Myers Squibb Company Common Stock 公司概况(来自维基百科)
百时美施贵宝 是源於美國的跨國製藥公司,於1989年由美國兩大藥廠百时美(Bristol-Myers)與施贵宝(Squibb)合併而成。前者在1887年由威廉·麥拉倫·布里斯托和約翰·雷普利·美爾斯在紐約州奧奈達縣柯林顿村成立的,而兩位創辦人都是當地汉密尔顿学院的畢業生;後者則是由發明家愛德華·羅賓森·斯貴博在1858年創立於布魯克林。
阅读更多
百时美施贵宝(Bristol-Myers Squibb,簡稱 BMS)是源於美國的跨國製藥公司,於1989年由美國兩大藥廠百时美(Bristol-Myers)與施贵宝(Squibb)合併而成。前者在1887年由威廉·麥拉倫·布里斯托和約翰·雷普利·美爾斯在紐約州奧奈達縣柯林顿村成立的,而兩位創辦人都是當地汉密尔顿学院的畢業生;後者則是由發明家愛德華·羅賓森·斯貴博在1858年創立於布魯克林。
百时美施贵宝公司致力於新藥的研究和開發,醫藥方面包括癌症治療、心臟血管、傳染病和新陳代謝類綜合症等領域,具有一定領導地位。旗下的全资附属公司美赞臣(Mead Johnson)(已於2017出售予利潔時)和康复宝(ConvaTec),分別致力於營養和保健/康復產品之研究和開發。
旗下公司
賽爾基因
2019年1月4日,百時美施貴寶斥資740億美元收賽爾基因,包括債務在內,交易總價值達950億美元。交易已得到兩家公司的董事會批准,預計在2019年第三季度完成。此後,施貴寶股東將持有新公司約69%的股份,賽爾基因股東將持有近31%股份。
康复宝
康复宝公司為一間專門生產醫療相關業務產品,主要產品包括造口、治理創傷用品、皮膚和傷口護理產品。
MyoKardia Inc
MyoKardia Inc為一間成立於2012年,總部位於美國加州南舊金山的心血管藥研發商。
公司代言人
兰斯·阿姆斯特朗 - 美國單車運動員,七屆环法自行车赛冠军。
来源:维基百科, CC BY-SA 4.0 · 在维基百科上查看 ↗
BMY 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
BMY 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
财务健康 债务、流动性、偿付能力 — 资产负债表强度
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
资本效率 资产周转率、库存周转率、应收账款周转率
股息 收益率、派息率、股息历史、5年CAGR
| 除息日 | 金额 |
|---|---|
| 2026年7月2日 | $0.6300 |
| 2026年4月2日 | $0.6300 |
| 2026年1月2日 | $0.6300 |
| 2025年10月3日 | $0.6200 |
| 2025年7月3日 | $0.6200 |
| 2025年4月4日 | $0.6200 |
| 2025年1月3日 | $0.6200 |
| 2024年10月4日 | $0.6000 |
| 2024年7月5日 | $0.6000 |
| 2024年4月4日 | $0.6000 |
| 2024年1月4日 | $0.6000 |
| 2023年10月5日 | $0.5700 |
| 2023年7月6日 | $0.5700 |
| 2023年4月6日 | $0.5700 |
| 2023年1月5日 | $0.5700 |
| 2022年10月6日 | $0.5400 |
| 2022年6月30日 | $0.5400 |
| 2022年3月31日 | $0.5400 |
| 2022年1月6日 | $0.5400 |
| 2021年9月30日 | $0.4900 |
BMY 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
- 强烈买入 6 17.1%
- 买入 8 22.9%
- 持有 19 54.3%
- 卖出 2 5.7%
- 强烈卖出 0 0.0%
12个月价格目标
24 位分析师 · 2026-08-24收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $2.04 | $1.60 | 0.44% |
| 2026年3月31日 | $1.58 | $1.43 | 0.15% |
| 2025年12月31日 | $1.26 | $1.13 | 0.13% |
| 2025年9月30日 | $1.63 | $1.52 | 0.11% |
| 2025年6月30日 | $1.46 | $1.08 | 0.38% |
| 2025年3月31日 | $1.80 | $1.51 | 0.29% |
同行比较(GICS 子行业) 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 17
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Cost of Revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B | $3.91B | $3.93B | |
| Gross Profit | · | · | · | · | · | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | |
| R&D Expense | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | |
| SG&A Expense | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B | $4.75B | $4.98B | $4.84B | $4.82B | |
| Operating Expenses | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B | $15.64B | $13.51B | $14.48B | $13.50B | |
| Interest Expense | · | · | $1.17B | $1.23B | $1.33B | $1.42B | $656M | $183M | $196M | $167M | $184M | $203M | |
| Interest Income | $586M | $478M | $449M | $171M | $39M | $121M | $464M | $173M | $126M | $97M | $101M | $101M | |
| Other Non-op | $-674M | $-893M | $1.16B | $-576M | $720M | $2.31B | $-938M | $854M | $1.69B | $1.45B | $187M | $-210M | |
| Pretax Income | $9.33B | $-8.38B | $8.44B | $7.71B | $8.10B | $-6.87B | $4.97B | $5.97B | $5.13B | $5.92B | $2.08B | $2.38B | |
| Income Tax | $2.27B | $554M | $400M | $1.37B | $1.08B | $2.12B | $1.51B | $1.02B | $4.16B | $1.41B | $446M | $352M | |
| Net Income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| EPS (Basic) | $3.47 | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.99 | $2.02 | $3.01 | $0.61 | $2.67 | $0.94 | $1.21 | |
| EPS (Diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | |
| Shares (Basic) | 2,034,000,000 | 2,027,000,000 | 2,069,000,000 | 2,130,000,000 | 2,221,000,000 | 2,258,000,000 | 1,705,000,000 | 1,633,000,000 | 1,645,000,000 | 1,671,000,000 | 1,667,000,000 | 1,657,000,000 | |
| Shares (Diluted) | 2,039,000,000 | 2,027,000,000 | 2,078,000,000 | 2,146,000,000 | 2,245,000,000 | 2,258,000,000 | 1,712,000,000 | 1,637,000,000 | 1,652,000,000 | 1,680,000,000 | 1,679,000,000 | 1,670,000,000 | |
| EBITDA | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M |
资产负债表 31
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B | $14.55B | $12.35B | $6.91B | $5.42B | $4.24B | $2.38B | $5.57B | |
| Short-term Investments | · | · | · | $130M | $2.99B | $1.28B | $3.05B | $1.85B | $1.39B | $2.11B | $1.89B | $1.86B | |
| Receivables | $9.59B | $9.01B | $8.88B | $8.15B | $7.98B | $7.22B | $6.48B | $4.64B | $4.35B | $3.77B | $2.95B | $2.10B | |
| Inventory | $2.69B | $2.56B | $2.66B | $2.34B | $2.10B | $2.07B | $4.29B | $1.20B | $1.17B | $1.24B | $1.22B | $1.56B | |
| Prepaid Expense | · | · | · | · | · | · | · | · | $576M | $570M | $625M | $470M | |
| Other Current Assets | $4.61B | $5.62B | $5.91B | $5.79B | $4.83B | $3.79B | $1.98B | $2.02B | $576M | $570M | $625M | $470M | |
| Current Assets | $29.39B | $29.78B | $31.77B | $27.27B | $33.26B | $30.19B | $29.35B | $17.72B | $14.85B | $13.70B | $10.41B | $14.61B | |
| PP&E (Net) | $7.54B | $7.14B | $6.65B | $6.25B | $6.05B | $5.89B | $6.25B | $5.03B | $5.00B | $4.98B | $4.41B | $4.42B | |
| PP&E (Gross) | $12.84B | $12.09B | $11.45B | $10.42B | $10.08B | $9.47B | $10.21B | $8.85B | $8.99B | $9.17B | $8.63B | $9.07B | |
| Accum. Depreciation | $5.29B | $4.95B | $4.80B | $4.16B | $4.03B | $3.58B | $3.96B | $3.82B | $3.99B | $4.19B | $4.22B | $4.65B | |
| Goodwill | $21.75B | $21.72B | $21.17B | $21.15B | $20.50B | $20.55B | $22.49B | $6.54B | $6.86B | $6.88B | $6.88B | $7.03B | |
| Intangibles | $19.10B | $23.31B | $27.07B | $35.86B | $42.53B | $53.24B | $63.97B | $1.09B | $1.21B | $1.39B | $1.42B | $1.75B | |
| Other Non-current Assets | $6.47B | $6.11B | $5.37B | $4.94B | $5.54B | $7.02B | $6.60B | $2.02B | $1.53B | $1.05B | $1.12B | $621M | |
| Total Assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B | |
| Accounts Payable | $3.58B | $3.60B | $3.26B | $3.04B | $2.95B | $2.71B | $2.44B | $1.89B | $2.25B | $1.66B | $1.56B | $2.49B | |
| Accrued Liabilities | · | · | · | · | · | · | · | $6.49B | $6.01B | $5.27B | $4.74B | $2.46B | |
| Short-term Debt | $2.26B | $2.05B | $3.12B | $4.26B | $4.95B | $2.34B | $3.35B | $1.70B | $987M | $109M | $139M | $590M | |
| Current Liabilities | $23.42B | $23.77B | $22.26B | $21.89B | $21.87B | $19.08B | $18.30B | $10.65B | $9.56B | $8.84B | $8.02B | $8.46B | |
| Capital Leases | $1.83B | $1.37B | $1.53B | $1.26B | $874M | $833M | $672M | $0 | · | · | · | · | |
| Deferred Tax | $222M | $369M | $338M | $2.17B | $4.50B | $5.41B | $6.45B | $19M | $45M | $47M | $31M | $60M | |
| Other Non-current Liabilities | $5.04B | $4.47B | $6.42B | $6.59B | $7.33B | $7.78B | $10.10B | $4.54B | $1.16B | $1.28B | $1.43B | $618M | |
| Total Liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B | $78.25B | $20.86B | $21.70B | $17.36B | $17.32B | $18.77B | |
| Long-term Debt | $44.83B | $49.43B | $39.53B | $38.95B | $44.37B | $50.34B | $46.15B | $6.89B | $6.97B | $6.46B | · | · | |
| Total Debt | $47.09B | $51.48B | $42.65B | $43.22B | $49.32B | $52.68B | $49.50B | $8.60B | $7.49B | $7.46B | $6.69B | $7.83B | |
| Common Stock | · | · | · | $292M | $292M | $292M | $292M | $221M | $221M | $221M | $221M | $221M | |
| Paid-in Capital | $46.39B | $46.02B | $45.68B | $45.16B | $44.36B | $44.33B | $43.71B | $2.08B | $1.90B | $1.73B | $1.46B | $1.51B | |
| Retained Earnings | $16.90B | $14.91B | $28.77B | $25.50B | $23.82B | $21.28B | $34.47B | $34.06B | $31.16B | $33.51B | $31.61B | $32.54B | |
| Treasury Stock | $43.58B | $43.66B | $43.77B | $38.62B | $31.26B | $26.24B | $25.36B | $19.57B | $19.25B | $16.78B | $16.56B | $16.99B | |
| AOCI | $-1.52B | $-1.24B | $-1.55B | $-1.28B | $-1.27B | $-1.84B | $-1.52B | $-2.76B | $-2.29B | $-2.50B | $-2.47B | $-2.42B | |
| Stockholders' Equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B | $16.18B | $14.27B | $14.85B | |
| Liabilities + Equity | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B |
现金流 19
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M | |
| Stock-based Comp | $553M | $507M | $518M | $457M | $583M | $779M | $441M | $221M | $199M | $205M | $235M | $213M | |
| Deferred Tax | $-965M | $-2.09B | $-3.29B | $-2.74B | $-1.39B | $983M | $-924M | $45M | $453M | $-204M | $-347M | $-542M | |
| Amort. of Intangibles | $3.50B | $9.00B | $9.20B | $9.70B | $10.20B | $9.90B | $1.30B | $198M | $190M | $178M | $183M | $286M | |
| Restructuring | $563M | $635M | $365M | $75M | $169M | $530M | $301M | $131M | $293M | $109M | $118M | $163M | |
| Other Non-cash | $3.50B | $16.12B | $-1.16B | $-1.26B | $-663M | $10.93B | $3.37B | $76M | $2.27B | $-1.99B | $3M | $1.01B | |
| Operating Cash Flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B | $5.28B | $3.06B | $2.10B | $3.15B | |
| CapEx | $1.31B | $1.25B | $1.21B | $1.12B | $973M | $753M | $836M | $951M | $1.05B | $1.22B | $820M | $526M | |
| Investing Cash Flow | $-4.13B | $-21.35B | $-2.29B | $-1.06B | $-538M | $-10.86B | $-9.91B | $-2.00B | $-66M | $1.48B | $-1.57B | $1.22B | |
| Debt Issued | $5.74B | $12.88B | $4.46B | $5.93B | $0 | $6.95B | $26.78B | $0 | $1.49B | $0 | $1.27B | · | |
| Net Debt Issued | $-5.20B | $10.01B | $576M | $-5.50B | $-6.02B | $4.20B | $17.52B | $-5M | $264M | $-15M | $-689M | $-676M | |
| Stock Repurchased | $0 | $0 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320M | $2.47B | $231M | · | · | |
| Net Stock Activity | $0 | $0 | $-5.16B | $-8.00B | $-6.29B | $-1.55B | $-7.30B | $-320M | $-2.47B | $-231M | · | · | |
| Dividends Paid | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B | |
| Financing Cash Flow | $-10.35B | $5.13B | $-9.42B | $-16.96B | $-16.22B | $-1.15B | $7.62B | $-3.54B | $-4.08B | $-2.65B | $-3.62B | $-2.44B | |
| Net Change in Cash | $-129M | $-1.17B | $2.19B | $-4.99B | $-657M | $2.15B | $5.91B | $1.49B | $1.18B | $1.85B | $-3.19B | $1.99B | |
| Taxes Paid | $3.26B | $3.90B | $4.30B | $5.40B | $3.50B | $3.40B | $1.50B | $747M | $546M | $2.00B | $577M | $544M | |
| Free Cash Flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.23B | $4.99B | $4.22B | $1.64B | $1.01B | $2.62B | |
| Levered FCF | · | · | $11.54B | $10.93B | $14.08B | $11.44B | $6.77B | $4.84B | $4.18B | $1.51B | $868M | $2.45B |
盈利能力 6
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% | 76.4% | 75.2% | |
| Net Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.9% | 22.9% | 9.4% | 12.6% | |
| Pretax Margin | 19.4% | -17.3% | 18.8% | 16.7% | 17.5% | -16.2% | 19.0% | 26.5% | 24.7% | 30.4% | 12.5% | 15.0% | |
| EBITDA Margin | 8.3% | 19.9% | 21.7% | 22.3% | 23.0% | 24.4% | 6.7% | 2.8% | 3.8% | 2.0% | 2.3% | 2.9% | |
| ROA | 7.7% | -9.5% | 8.4% | 6.1% | 6.1% | -7.4% | 3.7% | 14.3% | 3.0% | 13.2% | 4.9% | 6.0% | |
| ROE | 40.5% | -39.1% | 26.5% | 18.9% | 19.0% | -20.2% | 10.5% | 38.2% | 7.2% | 29.3% | 10.8% | 13.4% |
流动性与偿付能力 4
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.3 | 1.7 | |
| Quick Ratio | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 | 1.2 | 1.2 | 1.3 | 1.2 | 1.1 | 0.9 | 1.1 | |
| Debt / Equity | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.0 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | |
| LT Debt / Equity | 2.3 | 2.9 | 1.2 | 1.1 | 1.1 | 1.3 | 0.8 | 0.4 | 0.6 | 0.4 | 0.5 | 0.5 |
效率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | |
| Inventory Turnover | 5.3 | 5.4 | 4.3 | 4.6 | 4.8 | 3.7 | 2.9 | 5.5 | 5.0 | 4.0 | 2.8 | 2.6 | |
| Receivables Turnover | 5.2 | 5.4 | 5.3 | 5.7 | 6.1 | 6.2 | 4.7 | 5.0 | 5.1 | 5.8 | 6.6 | 8.4 |
增长率 8
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.22% | 7.3% | -2.5% | -0.49% | 9.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.5% | 1.4% | 1.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | 30.9% | -5.5% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 5.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | 26.8% | -9.5% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 3.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 4.4% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 6
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Net Income TTM | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| P/E | 15.6 | -12.8 | 13.3 | 24.4 | 20.0 | -15.5 | 31.9 | 17.3 | 100.5 | 22.1 | 74.0 | 49.2 | |
| Earnings Yield | 6.4% | -7.8% | 7.5% | 4.1% | 5.0% | -6.4% | 3.1% | 5.8% | 1.0% | 4.5% | 1.4% | 2.0% | |
| Payout Ratio | 71.5% | -54.4% | 59.1% | 73.2% | 62.8% | -45.2% | 77.9% | 53.1% | 255.9% | 57.1% | 158.3% | 119.7% | |
| Annual Payout | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B |
损益表 16
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B | $12.20B | $11.87B | $11.48B | $10.97B | $11.23B | $11.34B | $11.41B | $11.22B | |
| Cost of Revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B | $2.96B | $3.27B | $2.93B | $2.75B | $2.51B | $2.88B | $2.57B | $2.59B | $2.35B | |
| R&D Expense | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $3.19B | $2.37B | $2.90B | $2.69B | $2.48B | $2.24B | $2.26B | $2.32B | $2.51B | $2.42B | |
| SG&A Expense | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B | $1.98B | $1.93B | $2.37B | $2.07B | $2.00B | $1.93B | $1.76B | $2.27B | $1.93B | |
| Operating Expenses | $8.89B | $8.25B | $11.03B | $9.11B | $10.50B | $8.23B | $12.17B | $10.22B | $10.91B | $23.38B | $9.80B | $8.83B | $9.37B | $8.57B | $9.55B | $9.01B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $425M | · | $280M | $282M | $288M | · | $299M | |
| Interest Income | $101M | $104M | $148M | $161M | $139M | $138M | $114M | $94M | $87M | $183M | $145M | $107M | $95M | $102M | $82M | $52M | |
| Other Non-op | $61M | $-32M | $51M | $108M | $-494M | $-339M | $-305M | $-234M | $-273M | $-81M | $371M | $258M | $116M | $413M | $217M | $140M | |
| Pretax Income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175M | $1.68B | $1.29B | $-11.52B | $1.67B | $2.14B | $1.86B | $2.77B | $1.86B | $2.21B | |
| Income Tax | $770M | $561M | $384M | $919M | $460M | $509M | $99M | $461M | $-398M | $392M | $-88M | $203M | $-218M | $503M | $-166M | $601M | |
| Net Income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72M | $1.21B | $1.68B | $-11.91B | $1.76B | $1.93B | $2.07B | $2.26B | $2.02B | $1.61B | |
| EPS (Basic) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.21 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.94 | $0.99 | $1.08 | $0.95 | $0.75 | |
| EPS (Diluted) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.20 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.93 | $0.99 | $1.07 | $0.95 | $0.75 | |
| Shares (Basic) | 2,042,000,000 | 2,038,000,000 | -4,068,000,000 | 2,036,000,000 | 2,035,000,000 | 2,031,000,000 | -4,051,000,000 | 2,028,000,000 | 2,027,000,000 | 2,023,000,000 | -4,180,000,000 | 2,057,000,000 | 2,093,000,000 | 2,099,000,000 | -4,282,000,000 | 2,133,000,000 | |
| Shares (Diluted) | 2,048,000,000 | 2,047,000,000 | -4,078,000,000 | 2,039,000,000 | 2,038,000,000 | 2,040,000,000 | -4,056,000,000 | 2,031,000,000 | 2,029,000,000 | 2,023,000,000 | -4,201,000,000 | 2,064,000,000 | 2,102,000,000 | 2,113,000,000 | -4,315,000,000 | 2,148,000,000 | |
| EBITDA | · | $594M | · | · | · | $1.01B | · | · | · | $2.53B | · | · | · | $2.43B | · | · |
资产负债表 29
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B | $10.88B | $10.35B | $7.89B | $6.29B | $9.33B | · | $7.51B | $8.37B | $8.99B | · | $7.73B | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $171M | $358M | $274M | · | $1.29B | |
| Receivables | $9.08B | $7.95B | $9.59B | $9.62B | $9.71B | $9.06B | $9.01B | $9.32B | $9.75B | $8.83B | · | $8.41B | $8.12B | $7.85B | · | $8.02B | |
| Inventory | $2.74B | $2.76B | $2.69B | $2.76B | $2.74B | $2.67B | $2.56B | $3.33B | $3.08B | $2.98B | · | $2.44B | $2.36B | $2.60B | · | $2.07B | |
| Other Current Assets | $4.22B | $4.60B | $4.61B | $4.95B | $5.47B | $5.53B | $5.62B | $5.62B | $5.74B | $5.57B | · | $7.21B | $6.87B | $5.16B | · | $6.08B | |
| Current Assets | $28.58B | $27.21B | $29.39B | $35.63B | $33.22B | $30.78B | $29.78B | $28.07B | $26.89B | $28.67B | · | $27.63B | $28.07B | $27.09B | · | $26.80B | |
| PP&E (Net) | $7.79B | $7.66B | $7.54B | $7.35B | $7.37B | $7.21B | $7.14B | $6.90B | $6.84B | $6.75B | · | $6.48B | $6.36B | $6.28B | · | $6.04B | |
| PP&E (Gross) | $13.34B | $13.09B | $12.84B | $12.54B | $12.68B | $12.32B | $12.09B | $11.74B | $11.93B | $11.69B | · | $11.13B | $10.83B | $10.52B | · | $10.17B | |
| Accum. Depreciation | $5.55B | $5.43B | $5.29B | $5.20B | $5.31B | $5.11B | $4.95B | $4.84B | $5.09B | $4.94B | · | $4.65B | $4.48B | $4.24B | · | $4.14B | |
| Goodwill | $21.74B | $21.74B | $21.75B | $21.75B | $21.78B | $21.74B | $21.72B | $21.75B | $21.73B | $21.74B | $21.17B | $21.15B | $21.16B | $21.16B | $21.15B | $21.11B | |
| Intangibles | $17.39B | $18.24B | $19.10B | $20.46B | $21.38B | $22.49B | $23.31B | $26.96B | $29.43B | $32.76B | · | $28.95B | $31.30B | $33.57B | · | $38.18B | |
| Other Non-current Assets | $6.38B | $6.08B | $6.47B | $6.33B | $5.94B | $5.87B | $6.11B | $6.04B | $6.07B | $6.02B | · | $5.21B | $5.02B | $4.87B | · | $4.75B | |
| Total Assets | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B | |
| Accounts Payable | $4.16B | $4.23B | $3.58B | $4.29B | $5.43B | $4.00B | $3.60B | $3.47B | $3.75B | $3.54B | · | $2.81B | $3.07B | $3.19B | · | $2.60B | |
| Short-term Debt | $1.03B | $2.31B | $2.26B | $4.51B | $4.71B | $3.55B | $2.05B | $1.08B | $3.53B | $6.19B | · | $5.47B | $3.02B | $2.75B | · | $2.13B | |
| Current Liabilities | $18.66B | $19.16B | $23.42B | $28.14B | $27.53B | $24.07B | $23.77B | $22.64B | $23.27B | $25.82B | · | $23.46B | $20.15B | $19.09B | · | $18.93B | |
| Capital Leases | $1.73B | $1.77B | $1.83B | $1.85B | $1.55B | $1.36B | $1.37B | $1.48B | $1.44B | $1.56B | · | $1.51B | $1.34B | $1.37B | · | $845M | |
| Deferred Tax | $222M | $211M | $222M | $225M | $247M | $276M | $369M | $430M | $461M | $442M | · | $399M | $751M | $1.57B | · | $2.88B | |
| Other Non-current Liabilities | $4.34B | $4.85B | $5.04B | $5.46B | $4.94B | $4.48B | $4.47B | $4.73B | $4.99B | $6.73B | · | $6.20B | $5.90B | $6.66B | · | $6.68B | |
| Total Liabilities | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | $74.98B | $76.22B | $76.47B | $77.58B | $82.48B | · | $62.20B | $61.46B | $62.40B | · | $65.46B | |
| Long-term Debt | $42.86B | $44.14B | $44.83B | $48.72B | $48.95B | $49.51B | $49.43B | $49.55B | $51.95B | $52.36B | · | $37.01B | $37.07B | $37.33B | · | $38.87B | |
| Total Debt | $43.89B | $46.45B | · | $53.23B | $53.66B | $53.06B | · | $50.62B | $55.48B | $58.55B | · | $42.48B | $40.09B | $40.08B | · | $41.00B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | · | $292M | $292M | · | $292M | |
| Paid-in Capital | $46.50B | $46.37B | $46.39B | $46.27B | $46.13B | $46.01B | $46.02B | $45.90B | $45.77B | $45.66B | · | $44.85B | $45.30B | $45.14B | · | $44.96B | |
| Retained Earnings | $20.32B | $18.29B | $16.90B | $17.09B | $16.15B | $16.11B | $14.91B | $16.10B | $16.10B | $15.64B | · | $28.22B | $27.45B | $26.57B | · | $24.68B | |
| Treasury Stock | $43.50B | $43.52B | $43.58B | $43.59B | $43.59B | $43.60B | $43.66B | $43.67B | $43.69B | $43.70B | · | $43.08B | $39.68B | $38.81B | · | $36.41B | |
| AOCI | $-1.29B | $-1.37B | $-1.52B | $-1.51B | $-1.55B | $-1.42B | $-1.24B | $-1.47B | $-1.46B | $-1.40B | · | $-1.29B | $-1.39B | $-1.37B | · | $-841M | |
| Stockholders' Equity | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | $17.39B | $16.34B | $17.14B | $17.02B | $16.49B | · | $29.00B | $31.97B | $31.82B | · | $32.67B | |
| Liabilities + Equity | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B |
现金流 19
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $594M | $594M | $977M | $1.01B | $1.01B | $1.01B | $1.88B | $2.59B | $2.60B | $2.53B | $2.46B | $2.44B | $2.43B | $2.43B | $2.52B | $2.59B | |
| Stock-based Comp | $135M | $146M | $133M | $139M | $137M | $144M | $120M | $129M | $125M | $133M | $127M | $132M | $137M | $122M | $119M | $115M | |
| Deferred Tax | $-195M | $161M | $-392M | $-359M | $-437M | $223M | $-791M | $-256M | $-331M | $-711M | $-1.33B | $-327M | $-1.09B | $-548M | $-624M | $-645M | |
| Amort. of Intangibles | $471M | $472M | $906M | $867M | $864M | $863M | $1.80B | $2.40B | $2.40B | $2.40B | $2.30B | $2.30B | $2.30B | $2.30B | $2.30B | $2.50B | |
| Restructuring | $56M | $5M | $132M | $75M | $223M | $133M | $77M | $78M | $260M | $220M | $44M | $141M | $113M | $67M | $15M | $17M | |
| Other Non-cash | · | $-2.47B | · | · | · | $-1.88B | · | · | · | $12.79B | · | · | · | $-1.29B | · | · | |
| Operating Cash Flow | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | $1.95B | $4.44B | $5.59B | $2.33B | $2.83B | $4.25B | $4.75B | $1.89B | $2.97B | $3.31B | $3.69B | |
| CapEx | $305M | $347M | $370M | $320M | $361M | $260M | $378M | $324M | $262M | $284M | $330M | $342M | $259M | $278M | $346M | $247M | |
| Investing Cash Flow | $-1.61B | $-131M | $-1.46B | $-1.70B | $-473M | $-499M | $-196M | $-219M | $-1.32B | $-19.62B | $-1.35B | $-410M | $-329M | $-210M | $1.21B | $-2.08B | |
| Debt Issued | · | · | $5.74B | $0 | $0 | $0 | $0 | $0 | $0 | $12.88B | · | · | · | · | $26M | $0 | |
| Net Debt Issued | · | $-500M | · | · | · | $0 | · | · | · | $0 | · | · | · | $-1.64B | · | · | |
| Stock Repurchased | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $4.00B | $905M | $250M | $2.42B | $701M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-250M | · | $-701M | |
| Dividends Paid | $1.29B | $1.28B | $1.26B | $1.26B | $1.26B | $1.26B | $1.22B | $1.22B | $1.22B | $1.21B | $1.16B | $1.19B | $1.20B | $1.20B | $1.15B | $1.15B | |
| Financing Cash Flow | $-2.63B | $-1.56B | $-6.03B | $-1.49B | $-1.84B | $-993M | $-1.64B | $-3.85B | $-4.02B | $14.64B | $967M | $-5.16B | $-2.17B | $-3.05B | $-3.25B | $-4.54B | |
| Net Change in Cash | $-861M | $-635M | $-5.51B | $3.12B | $1.74B | $528M | $2.45B | $1.60B | $-3.04B | $-2.19B | $3.95B | $-857M | $-623M | $-277M | $1.37B | $-3.00B | |
| Taxes Paid | · | $239M | $1.06B | $400M | $1.56B | $235M | $800M | $1.00B | $1.91B | $187M | $200M | $1.00B | $2.95B | $149M | $1.50B | $1.20B | |
| Free Cash Flow | · | $757M | · | · | · | $1.69B | · | · | · | $2.55B | · | · | · | $2.69B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2.11B | · | · | · | $2.46B | · | · |
盈利能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 25.6% | 23.3% | · | 18.0% | 10.7% | 21.9% | · | 10.2% | 13.8% | -100.4% | · | 17.6% | 18.5% | 20.0% | · | 14.3% | |
| Pretax Margin | 31.5% | 28.2% | · | 25.5% | 14.4% | 26.5% | · | 14.1% | 10.5% | -97.1% | · | 19.5% | 16.6% | 24.4% | · | 19.7% | |
| EBITDA Margin | · | 5.2% | · | · | · | 9.0% | · | · | · | 21.3% | · | · | · | 21.4% | · | · | |
| ROA | 3.6% | 3.0% | · | 2.3% | 1.4% | 2.6% | · | 1.3% | 1.8% | -12.3% | · | 2.0% | 2.1% | 2.3% | · | 1.5% | |
| ROE | 16.7% | 14.3% | · | 12.3% | 7.6% | 14.5% | · | 5.2% | 6.9% | -49.3% | · | 6.2% | 6.4% | 7.1% | · | 4.6% |
流动性与偿付能力 4
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.2 | 1.4 | 1.4 | · | 1.4 | |
| Quick Ratio | 1.0 | 0.9 | · | 0.9 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | |
| Debt / Equity | 2.0 | 2.3 | · | 2.9 | 3.1 | 3.1 | · | 3.0 | 3.3 | 3.6 | · | 1.5 | 1.3 | 1.3 | · | 1.3 | |
| LT Debt / Equity | 1.9 | 2.1 | · | 2.4 | 2.6 | 2.7 | · | 2.8 | 2.9 | 3.0 | · | 1.1 | 1.1 | 1.1 | · | 1.1 |
效率 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.1 | 1.2 | 1.1 | · | 1.0 | 1.2 | 1.0 | · | 1.1 | 1.3 | 1.1 | · | 1.1 | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.4 | · | 1.3 | 1.4 | 1.5 | · | 1.4 |
估值 (TTM) 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.95B | $47.18B | · | $47.58B | $47.56B | $47.16B | · | $46.92B | $46.26B | $45.39B | · | $44.75B | $45.67B | $46.09B | · | $46.38B | |
| Net Income TTM | $9.51B | $8.64B | · | $7.18B | $6.66B | $-6.56B | · | $-7.09B | $-6.23B | $-5.65B | · | $7.87B | $7.36B | $6.57B | · | $5.85B | |
| P/E | 12.4 | 14.3 | · | 12.8 | 14.2 | -18.7 | · | -14.7 | -13.2 | -18.7 | · | 15.5 | 18.4 | 22.6 | · | 26.4 | |
| Earnings Yield | 8.1% | 7.0% | · | 7.8% | 7.1% | -5.3% | · | -6.8% | -7.6% | -5.3% | · | 6.4% | 5.4% | 4.4% | · | 3.8% | |
| Payout Ratio | · | 47.9% | · | · | · | 51.2% | · | · | · | -10.2% | · | · | · | 52.9% | · | · |
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| 净收入 | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B |
| 稀释后每股收益 (EPS) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 |
| 流动比率 | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 |
| 速动比率 | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B |
最新新闻 提及该公司的近期头条新闻
- Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
- Bristol Myers Squibb to build $2.3 billion Houston campus
- Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
- The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today
- Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
- $400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- Bill Ackman Runs a $14 Billion Fund on Just 11 Stocks. These Are His 3 Biggest Bets Right Now.
- Is Bristol-Myers Squibb Stock Underperforming the Dow?
- Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存,并会跟随您浏览所有股票。
机构持有人 (13F) 2785 家申报者 · $58.1B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 159 (-159 与上一季度对比) | 154 (+18 与上一季度对比) | 1006 (-29 与上一季度对比) | 987 (+89 与上一季度对比) | +55.3M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $7682927263 | 133337856 | 13.22% | 股份 |
| STATE STREET CORP | $5900803123 | 102408940 | 10.15% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3894809793 | 67594755 | 6.70% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $2858273235 | 49750183 | 4.92% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2700823125 | 46873015 | 4.65% | 股份 |
| NORGES BANK | $2124256834 | 36866658 | 3.66% | 股份 |
| PRIMECAP MANAGEMENT CO/CA/ | $1436115120 | 24923900 | 2.47% | 股份 |
| AMERIPRISE FINANCIAL INC | $1308030705 | 22705049 | 2.25% | 股份 |
| Independent Franchise Partners LLP | $1255703498 | 21792841 | 2.16% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $938463230 | 16287109 | 1.61% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $660776941 | 11467840 | 1.14% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $585933423 | 10168924 | 1.01% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $581119768 | 10085383 | 1.00% | 股份 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $494716447 | 8585846 | 0.85% | 股份 |
| BlackRock, Inc. | $492399085 | 8545628 | 0.85% | 股份 |
| FMR LLC | $451250223 | 7831486 | 0.78% | 股份 |
| TWO SIGMA ADVISERS, LP | $446094588 | 8270200 | 0.77% | 股份 |
| Robeco Institutional Asset Management B.V. | $417435581 | 7244630 | 0.72% | 股份 |
| GOLDMAN SACHS GROUP INC | $392167333 | 6806097 | 0.67% | 股份 |
| FIRST TRUST ADVISORS LP | $344672508 | 5981822 | 0.59% | 股份 |
| Capital International Investors | $340767005 | 5913752 | 0.59% | 股份 |
| Swiss National Bank | $331822056 | 5758800 | 0.57% | 股份 |
| VAN ECK ASSOCIATES CORP | $325076944 | 5641738 | 0.56% | 股份 |
| National Pension Service | $321412139 | 5578135 | 0.55% | 股份 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $319229612 | 5540268 | 0.55% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $316480270 | 5492542 | 0.54% | 股份 |
| Legal & General Group Plc | $315258552 | 5471339 | 0.54% | 股份 |
| M&G PLC | $306949282 | 5292229 | 0.53% | 股份 |
| NORDEA INVESTMENT MANAGEMENT AB | $300773017 | 5232200 | 0.52% | 股份 |
| Sumitomo Mitsui Trust Group, Inc. | $293408012 | 5092121 | 0.50% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $288555718 | 4757720 | 0.50% | 股份 |
| Vanguard Global Advisers, LLC | $270856466 | 4700737 | 0.47% | 股份 |
| VANGUARD ASSET MANAGEMENT, Ltd | $266201519 | 4619950 | 0.46% | 股份 |
| California Public Employees Retirement System | $263375546 | 4570905 | 0.45% | 股份 |
| BANK OF AMERICA CORP /DE/ | $263115723 | 4566396 | 0.45% | 股份 |
| VANGUARD GROUP INC | $247970649 | 4597157 | 0.43% | 股份 |
| Caisse de depot et placement du Quebec | $243646343 | 4228503 | 0.42% | 股份 |
| CANADA PENSION PLAN INVESTMENT BOARD | $241222903 | 4186444 | 0.42% | 股份 |
| JANE STREET GROUP, LLC | $224896622 | 3903100 | 0.39% | 买入期权 |
| WELLINGTON MANAGEMENT GROUP LLP | $214546630 | 3723475 | 0.37% | 股份 |
| Employees Provident Fund Board | $209755987 | 3640333 | 0.36% | 股份 |
| CITADEL ADVISORS LLC | $194502072 | 3375600 | 0.33% | 卖出期权 |
| RHUMBLINE ADVISERS | $192874042 | 3347347 | 0.33% | 股份 |
| LPL Financial LLC | $188151217 | 3265381 | 0.32% | 股份 |
| BARCLAYS PLC | $186163076 | 3230876 | 0.32% | 股份 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $185255963 | 3215133 | 0.32% | 股份 |
| UBS Group AG | $180243196 | 3128136 | 0.31% | 股份 |
| Qube Research & Technologies Ltd | $178273860 | 3093958 | 0.31% | 股份 |
| Artemis Investment Management LLP | $175941518 | 3053480 | 0.30% | 股份 |
| SEB Asset Management AB | $165520833 | 2872632 | 0.28% | 股份 |
| Ensign Peak Advisors, Inc | $165119502 | 2865663 | 0.28% | 股份 |
| CITADEL ADVISORS LLC | $157769322 | 2738100 | 0.27% | 买入期权 |
| JANE STREET GROUP, LLC | $152525902 | 2647100 | 0.26% | 卖出期权 |
| NATIXIS | $145152674 | 2519137 | 0.25% | 股份 |
| AustralianSuper Pty Ltd | $140209857 | 2433354 | 0.24% | 股份 |
| Mirae Asset Global Investments Co., Ltd. | $138044440 | 2395773 | 0.24% | 股份 |
| Bank of New York Mellon Corp | $136334163 | 2366091 | 0.23% | 股份 |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $132803901 | 2304823 | 0.23% | 股份 |
| PANAGORA ASSET MANAGEMENT INC | $132622456 | 2301674 | 0.23% | 股份 |
| Capital World Investors | $129313224 | 2244242 | 0.22% | 股份 |
| NEW YORK STATE COMMON RETIREMENT FUND | $129300432 | 2244020 | 0.22% | 股份 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $125419207 | 2176661 | 0.22% | 股份 |
| RAYMOND JAMES FINANCIAL INC | $123353032 | 2140802 | 0.21% | 股份 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $122879893 | 2132591 | 0.21% | 股份 |
| PFA Pension, Forsikringsaktieselskab | $121829832 | 2114367 | 0.21% | 股份 |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $120528714 | 2234496 | 0.21% | 股份 |
| MACKENZIE FINANCIAL CORP | $118944044 | 2064284 | 0.20% | 股份 |
| Pictet Asset Management Holding SA | $116783155 | 2026687 | 0.20% | 股份 |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $116161574 | 2015994 | 0.20% | 股份 |
| TD Asset Management Inc | $115669154 | 2007448 | 0.20% | 股份 |
| SUSQUEHANNA ADVISORS GROUP, INC. | $115240000 | 2000000 | 0.20% | 买入期权 |
| MACQUARIE GROUP LTD | $111978478 | 1943396 | 0.19% | 股份 |
| Vinva Investment Management Ltd | $109557913 | 1870866 | 0.19% | 股份 |
| ENVESTNET ASSET MANAGEMENT INC | $108509833 | 1883218 | 0.19% | 股份 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $106751521 | 1760124 | 0.18% | 股份 |
| LMR Partners LLP | $106066896 | 1840800 | 0.18% | 卖出期权 |
| AVIVA PLC | $103620639 | 1798345 | 0.18% | 股份 |
| PRUDENTIAL FINANCIAL INC | $103202606 | 1791090 | 0.18% | 股份 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $102378000 | 1776782 | 0.18% | 股份 |
| STOREBRAND ASSET MANAGEMENT AS | $101037131 | 1753508 | 0.17% | 股份 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $100790172 | 1749222 | 0.17% | 股份 |
| BANK OF NOVA SCOTIA | $99453647 | 1726026 | 0.17% | 股份 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $98875920 | 1716000 | 0.17% | 股份 |
| KLP KAPITALFORVALTNING AS | $94673002 | 1643058 | 0.16% | 股份 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $90576678 | 1567009 | 0.16% | 股份 |
| BANK OF MONTREAL /CAN/ | $89684378 | 1556480 | 0.15% | 股份 |
| Douglas Lane & Associates, LLC | $89667305 | 1556184 | 0.15% | 股份 |
| PNC Financial Services Group, Inc. | $89112096 | 1546548 | 0.15% | 股份 |
| Walleye Trading LLC | $88014550 | 1527500 | 0.15% | 买入期权 |
| Korea Investment CORP | $86518389 | 1501534 | 0.15% | 股份 |
| APG Asset Management N.V. | $85242422 | 1691386 | 0.15% | 股份 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $85175958 | 1478236 | 0.15% | 股份 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $84205059 | 1764695 | 0.14% | 股份 |
| Mariner, LLC | $83309670 | 1445809 | 0.14% | 股份 |
| Retirement Systems of Alabama | $80928212 | 1404516 | 0.14% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $80695542 | 1400478 | 0.14% | 股份 |
| Nuveen Asset Management, LLC | $76733142 | 1356668 | 0.13% | 股份 |
| CWM, LLC | $76220909 | 1256734 | 0.13% | 股份 |
| Eurizon Capital SGR S.p.A. | $70986984 | 1230296 | 0.12% | 股份 |
| Aberdeen Group plc | $70798674 | 1228717 | 0.12% | 股份 |
公司内部人士 102 位内幕人士 · 65 位高管 · 37 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | 2025年6月13日 G | 125439 | 0 | 0 | $0 |
| Peter R Dolan | Former CEO | 2006年9月8日 F | 571673 | 0 | 0 | $0 |
| David V Elkins | EVP, Chief Financial Officer | 2026年4月1日 S | 159248 | 0 | 3 | $-4500496 |
| Jean-Marc Huet | EVP & CFO | 2009年4月30日 P | 25000 | 0 | 0 | $0 |
| Benjamin Hickey | President, RayzeBio Org. | 2025年5月9日 S | 0 | 0 | 0 | $0 |
| Lynelle Hoch | President, Cell Therapy Org. | 2025年3月10日 A | 4711 | 0 | 0 | $0 |
| James B D Palmer DR | CSO & President, PRI | 2004年3月2日 A | 178889 | 0 | 0 | $0 |
| Dean J Mitchell | President, U.S. Primary Care | 2003年9月10日 A | 60000 | 0 | 0 | $0 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 2026年8月1日 M | 24997 | 0 | 0 | $0 |
| Cari Gallman | EVP, General Counsel | 2026年8月1日 M | 13649 | 0 | 0 | $0 |
| Bartie Wendy Short | EVP, Corporate Affairs | 2026年6月3日 F | 12081 | 0 | 0 | $0 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | 2025年7月1日 A | — | 0 | 0 | $0 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | 2025年5月1日 J | 12439 | 0 | 0 | $0 |
| Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 2025年4月25日 P | 83513 | 0 | 0 | $0 |
| Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 2025年4月1日 M | 13797 | 0 | 0 | $0 |
| Phil M Holzer | SVP and Controller | 2025年3月10日 A | 14967 | 0 | 0 | $0 |
| Ahn Amanda Poole | EVP, Chief People Officer | 2025年3月10日 A | 5196 | 0 | 0 | $0 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 2025年3月10日 A | 16102 | 0 | 0 | $0 |
| Robert M Plenge | EVP, Chief Research Officer | 2025年3月10日 A | 15839 | 0 | 0 | $0 |
| Sandra Leung | EVP, General Counsel | 2025年3月10日 A | 364296 | 0 | 0 | $0 |
| Giovanni Caforio | Executive Chair of the Board | 2024年3月10日 M | 432266 | 0 | 0 | $0 |
| Ann Powell Judge | EVP, Chief Human Resources | 2023年8月24日 S | 27868 | 0 | 0 | $0 |
| Michelle Weese | EVP, Corporate Affairs | 2023年7月1日 M | 3453 | 0 | 0 | $0 |
| Rupert Vessey | EVP & President, Research | 2023年5月3日 S | 47751 | 0 | 0 | $0 |
| Sharon Greenlees | SVP & Controller | 2023年5月2日 M | 609 | 0 | 0 | $0 |
| Elizabeth Mily | EVP, Strategy & BD | 2023年4月1日 M | 34734 | 0 | 0 | $0 |
| Karen Murphy Santiago | SVP & Controller | 2022年3月14日 S | 16704 | 0 | 0 | $0 |
| Paul Von Autenried | EVP, Chief Information Officer | 2021年11月24日 S | 63536 | 0 | 0 | $0 |
| Adam Dubow | SVP,ChiefCompliance&EthicsOff. | 2021年7月30日 S | 13777 | 0 | 0 | $0 |
| Joseph Eid | SVP,Head Glob. Medical Affairs | 2021年6月3日 M | 9485 | 0 | 0 | $0 |
| Louis S Schmukler | EVP,Pres.,Glob.Prod. & Supply | 2021年5月10日 S | 31956 | 0 | 0 | $0 |
| Kathryn Metcalfe | EVP, Corporate Affairs | 2020年3月10日 A | — | 0 | 0 | $0 |
| John E Elicker | EVP, Investor Relations | 2020年3月10日 M | 70946 | 0 | 0 | $0 |
| Charles A Bancroft | EVP, Head of Integration | 2020年3月10日 M | 137534 | 0 | 0 | $0 |
| Paul Biondi | SVP, Head of Strategy & BD | 2019年10月2日 M | 6214 | 0 | 0 | $0 |
| Thomas J. Lynch Jr. | EVP & Chief Scientific Officer | 2019年4月3日 M | 22223 | 0 | 0 | $0 |
| Murdo Gordon | EVP, Chief Commercial Officer | 2018年8月1日 M | 49424 | 0 | 0 | $0 |
| Joseph C Caldarella | SVP & Controller | 2017年9月6日 S | 46297 | 0 | 0 | $0 |
| Anne Nielsen | Chief Compliance & Ethics Off | 2017年9月3日 M | 37974 | 0 | 0 | $0 |
| Emmanuel Blin | SVP, Chief Strategy Officer | 2017年3月10日 A | 20138 | 0 | 0 | $0 |
| Francis M Cuss | EVP & CSO | 2017年3月10日 M | 321906 | 0 | 0 | $0 |
| Samuel J Moed | SVP, Strat Plan & Analysis | 2015年3月13日 S | 31015 | 0 | 0 | $0 |
| Brian Daniels | SVP Global Dev & Med Affairs | 2014年7月1日 M | 94374 | 0 | 0 | $0 |
| Frances K Heller | SVP, Business Development | 2014年3月10日 A | 4174 | 0 | 0 | $0 |
| Elliot Sigal | EVP, CSO & President R&D | 2013年6月3日 M | 148221 | 0 | 0 | $0 |
| Beatrice J Cazala | EVP Commercial Operations | 2013年5月31日 S | 173375 | 0 | 0 | $0 |
| John E Celentano | SVP HR Public Affairs & Philan | 2012年3月6日 M | 142142 | 0 | 0 | $0 |
| Jeremy M Levin | SVP Strat Transactions | 2011年10月1日 M | 43689 | 0 | 0 | $0 |
| De Notaristefani Carlo | Pres Tech Ops & Supp Fnctns | 2011年6月14日 M | 7578 | 0 | 0 | $0 |
| Anthony C Hooper | SVP ComOps Pres USJap Int | 2011年5月13日 M | 203170 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
激进投资者及 5%+ 股东 11 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION ×3 申报 | 2020年7月16日 | — | 初始申报 | — | SEC |
| Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP | 2019年2月27日 | — | 初始申报 | 被动投资 | SEC |
| S.S. OR ×3 申报 | 2009年12月23日 | — | 初始申报 | — | SEC |
| Medarex, Inc. S.S. OR, S.S. OR | 2009年11月25日 | — | 初始申报 | — | SEC |
| Identification Nos. of Above Persons (entities only) Bristol-Myers Squibb Company ×2 申报 | 2009年2月27日 | — | 初始申报 | — | SEC |
| Bristol -Myers Squibb Company, Bristol -Myers Squibb Biologics Company ×3 申报 | 2008年10月8日 | — | 初始申报 | — | SEC |
| Bristol-Myers Squibb Company I.R.S. Employer Identification Number 22-079-0350 ×3 申报 | 2003年6月6日 | — | 初始申报 | — | SEC |
| 未披露的报告人 | 2003年4月16日 | — | 初始申报 | — | SEC |
| 未披露的报告人 | 2003年2月3日 | — | 初始申报 | — | SEC |
| 未披露的报告人 | 2002年3月6日 | — | 初始申报 | — | SEC |
| 未披露的报告人 | 2002年2月6日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 296 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 6.29% | 39590 NS | 2026年6月30日 | N-PORT |
| RDIV · Invesco Exchange-Traded Fund Trus... | 5.25% | 1134150 SH | 2026年8月21日 | 每日 |
| ROPE · EA Series Trust | 4.97% | 7379 NS | 2026年5月29日 | N-PORT |
| IHE · iShares Trust | 4.65% | 1223984 SH | 2026年8月21日 | 每日 |
| CAMX · ADVISORS' INNER CIRCLE FUND | 4.10% | 44768 NS | 2026年4月30日 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund ... | 3.50% | 6427 NS | 2026年4月30日 | N-PORT |
| FDL · First Trust Exchange-Traded Fund | 3.43% | 4337329 NS | 2026年6月30日 | N-PORT |
| CANC · Tema ETF Trust | 3.30% | 101680 NS | 2026年5月31日 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 3.21% | 2332 NS | 2026年4月30日 | N-PORT |
| AGNG · Global X Funds | 2.98% | 42594 NS | 2026年5月31日 | N-PORT |
| SCHD · SCHWAB STRATEGIC TRUST | 2.93% | 48641121 NS | 2026年5月31日 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 2.78% | 224546 SH | 2026年8月21日 | 每日 |
| ABFL · Abacus FCF ETF Trust | 2.76% | 226688 NS | 2026年4月30日 | N-PORT |
| HDV · iShares Trust | 2.62% | 6134190 SH | 2026年8月21日 | 每日 |
| ACEP · EA Series Trust | 2.52% | 44211 NS | 2026年5月29日 | N-PORT |
| SIXH · EXCHANGE TRADED CONCEPTS TRUST | 2.47% | 234394 NS | 2026年5月31日 | N-PORT |
| SIXA · EXCHANGE TRADED CONCEPTS TRUST | 2.47% | 210030 NS | 2026年5月31日 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 2.45% | 148728 NS | 2026年5月31日 | N-PORT |
| GEND · Spinnaker ETF Series | 2.18% | 1612 NS | 2026年4月30日 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 2.10% | 38747 SH | 2026年8月21日 | 每日 |
| HRTS · Tema ETF Trust | 2.09% | 18939 NS | 2026年5月31日 | N-PORT |
| FDIV · EA Series Trust | 2.07% | 24896 NS | 2026年4月30日 | N-PORT |
| IYH · iShares Trust | 2.06% | 1218183 SH | 2026年8月21日 | 每日 |
| SPHD · Invesco Exchange-Traded Fund Trus... | 2.06% | 1086835 SH | 2026年8月21日 | 每日 |
| GCOW · Pacer Funds Trust | 2.03% | 1123894 NS | 2026年4月30日 | N-PORT |
| COWZ · Pacer Funds Trust | 2.03% | 6082360 NS | 2026年4月30日 | N-PORT |
| QQWZ · Pacer Funds Trust | 2.03% | 15628 NS | 2026年4月30日 | N-PORT |
| SPDV · ETF Series Solutions | 2.02% | 30055 NS | 2026年4月30日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1.99% | 938456 NS | 2026年4月30日 | N-PORT |
| VLLU · Harbor ETF Trust | 1.98% | 1422 NS | 2026年4月30日 | N-PORT |
| BMVP · Invesco Exchange-Traded Fund Trust | 1.93% | 31120 SH | 2026年8月21日 | 每日 |
| PEY · Invesco Exchange-Traded Fund Trust | 1.83% | 327924 SH | 2026年8月21日 | 每日 |
| SDOG · ALPS ETF Trust | 1.83% | 441820 NS | 2026年5月31日 | N-PORT |
| RFDA · ALPS ETF Trust | 1.82% | 27812 NS | 2026年5月31日 | N-PORT |
| CURE · Direxion Shares ETF Trust | 1.78% | 40606 NS | 2026年4月30日 | N-PORT |
| FLOW · Global X Funds | 1.78% | 8912 NS | 2026年5月31日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 1.73% | 6137665 SH | 2026年8月19日 | 每日 |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.70% | 213437 SH | 2026年8月21日 | 每日 |
| RXL · ProShares Trust | 1.68% | 21228 NS | 2026年5月31日 | N-PORT |
| GMOV · GMO ETF Trust | 1.66% | 26358 NS | 2026年5月31日 | N-PORT |
| VMAX · Lattice Strategies Trust | 1.65% | 12671 NS | 2026年4月30日 | N-PORT |
| IXJ · iShares Trust | 1.61% | 1073117 SH | 2026年8月21日 | 每日 |
| NULV · Nushares ETF Trust | 1.57% | 539514 NS | 2026年4月30日 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.54% | 13556 NS | 2026年4月30日 | N-PORT |
| NUDV · Nushares ETF Trust | 1.54% | 11473 NS | 2026年4月30日 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1.47% | 415736 SH | 2026年8月21日 | 每日 |
| COWG · Pacer Funds Trust | 1.47% | 526151 NS | 2026年4月30日 | N-PORT |
| REVS · Columbia ETF Trust I | 1.46% | 68134 NS | 2026年4月30日 | N-PORT |
| TMFE · RBB Fund, Inc. | 1.45% | 21473 NS | 2026年5月31日 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1.43% | 64178 NS | 2026年4月30日 | N-PORT |